Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$0.54
-$0.04(-9.27%)
At close: 4:00 PM EST
$0.54
-$0.04(-9.27%)
Day’s Range― - ―
52-Week Range$0.33 - $4.78
Previous CloseN/A
Volume845.14K
Average Volume (3M)272.78K
Market Cap
$6.36M
Enterprise Value$13.85M
Total Cash (Recent Filing)$11.64M
Total Debt (Recent Filing)$23.38M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding14,410,621
10 Day Avg. Volume360,131
30 Day Avg. Volume272,777
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.94
Price to Sales (P/S)0.75
P/FCF Ratio-0.30
Enterprise Value/Market Cap2.18
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit54.97
Enterprise Value/Ebitda-0.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.78
Revenue Forecast (FY)$12.70M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained double-digit organic revenue growth and an initial commercial inflection indicate growing clinical adoption of LungFit. Durable top-line momentum supports scaling consumable sales and service annuities, which underpin longer-term recurring revenue as installed base expands.
Improved Gross Profit And Operating EfficiencyA swing to positive gross profit plus meaningful SG&A and R&D reductions demonstrates progress toward unit economics and operating leverage. If sustained, these structural improvements lower the break-even threshold and improve the path to free cash flow as volumes rise.
Broadened Commercial Footprint And High RetentionAccess via major GPOs and broad international clearances materially improves distribution scale and hospital penetration. High customer renewal suggests clinical stickiness, supporting recurring disposable sales and stronger long-term monetization of installed devices.
Bears Say
Heavy Cash Burn And Constrained LiquidityPersistent negative operating and free cash flows require external financing to sustain growth. With cash on hand below one year of recent burn and material long-term debt, the company faces meaningful refinancing risk that can limit investments in commercialization and R&D over the medium term.
Gen 2 Approval Is A Single-point Growth DependencyManagement’s step-change revenue projection hinges on regulatory approval and timely commercial execution of Gen 2. Reliance on a single product/label expansion creates binary regulatory and timing risk that could materially delay TAM expansion and revenue scaling if FDA or commercialization setbacks occur.
Deep Cumulative Losses And Eroded Equity BaseLarge recurring net losses have eroded shareholders’ equity and depressed returns on capital. A reduced equity cushion limits financial flexibility, increases dilution risk for future financings, and constrains the company’s ability to absorb setbacks while executing longer-term commercialization plans.
Beyond Air News
XAIR FAQ
What was Beyond Air’s price range in the past 12 months?
Beyond Air lowest stock price was $0.33 and its highest was $4.78 in the past 12 months.
What is Beyond Air’s market cap?
Beyond Air’s market cap is $6.36M.
When is Beyond Air’s upcoming earnings report date?
Beyond Air’s upcoming earnings report date is Aug 11, 2026 which is in 33 days.
How were Beyond Air’s earnings last quarter?
Beyond Air released its earnings results on Jun 26, 2026. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.567 by -$0.203.
Is Beyond Air overvalued?
According to Wall Street analysts Beyond Air’s price is currently Overvalued.
Does Beyond Air pay dividends?
Beyond Air does not currently pay dividends.
What is Beyond Air’s EPS estimate?
Beyond Air’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyond Air have?
Beyond Air has 14,410,621 shares outstanding.
What happened to Beyond Air’s price movement after its last earnings report?
Beyond Air reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.567. Following the earnings report the stock price went up 3.774%.
Which hedge fund is a major shareholder of Beyond Air?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial progress: strong revenue growth (>107% to $7.7M), improved gross profit and operating results, high customer retention (~90%), expanded GPO relationships and global clearances, and a compelling product roadmap with Gen 2 that could materially expand the addressable market. Offsetting these positives are remaining sizable net losses ($33.2M), limited cash on hand ($17.3M) versus $21.6M of long-term debt, increased other expenses, a Nasdaq compliance-driven reverse split, and dependence on uncertain FDA timing for Gen 2 approval (which underpins 2027 guidance). Overall, momentum and execution improvements are evident, but material execution and financing/regulatory risks remain.View all XAIR earnings summariesTechnical Analysis
Ownership Overview
62.97% Insiders
1.56% Mutual Funds
4.29% Other Institutional Investors
30.75% Public Companies and
Individual Investors